A more comprehensive understanding of VCAN based mechanisms contributing to peritoneal dissemination and patient responses to therapy will potentially result in a more personalised approach in CRC patients with PM, ultimately leading to better treatment outcomes. The gene discussed is VCAN; the disease is colorectal carcinoma.